Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 155

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 155
---
 results of preclinical studies and clinical trials for our product candidates, including whether and when to advance our diverse portfolio of product candidates; •the clinical development plans we establish for these product candidates; •the timelines of our clinical trials and the overall costs to finish the clinical trials; •the number and characteristics of product candidates that we develop; •the outcome, timing and cost of meeting regulatory requirements established by the FDA, European Medicines Agency and other comparable foreign regulatory authorities; •the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; •the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates; •the extent to which we enter into additional collaboration agreements with regard to product discovery or acquire or in -licenseproducts or technologies; •the effect of competing technological and market developments; •the cost and timing of completion of commercial -scaleoutsourced manufacturing activities; and •the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own. 81 Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. This additional funding may not be sufficient for us to fund any of our products through regulatory approval. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also may be required to seek collaborators for any of our product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Market volatility and unforeseen events, such as the COVID -19pandemic and the conflict between Russia and Ukraine or in the Middle East, could also